Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03169777
Other study ID # QUILT-3.050
Secondary ID
Status Withdrawn
Phase Phase 1/Phase 2
First received
Last updated
Start date August 2018
Est. completion date March 2019

Study information

Verified date October 2017
Source ImmunityBio, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with recurrent and metastatic CRC.


Description:

Treatment will be administered in 2 phases, an induction and a maintenance phase, as described below. Subjects will continue induction treatment for up to 1 year or until they experience progressive disease (PD) or unacceptable toxicity (not correctable with dose reduction), withdraw consent, or if the Investigator feels it is no longer in the subject's best interest to continue treatment. Those who have a complete response (CR) in the induction phase will enter the maintenance phase of the study. Subjects may remain in the maintenance phase of the study for up to 1 year. Treatment will continue in the maintenance phase until the subject experiences PD or unacceptable toxicity (not correctable with dose reduction), withdraws consent, or if the Investigator feels it is no longer in the subject's best interest to continue treatment.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 2019
Est. primary completion date January 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years. 2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or IEC guidelines. 3. Histologically confirmed recurrent or metastatic CRC. 4. ECOG performance status of 0 to 2. 5. Have at least 1 measurable lesion of = 1.5 cm. 6. Must have a recent tumor biopsy specimen obtained following the conclusion of the most recent anticancer treatment. If an historic specimen is not available, the subject must be willing to undergo a biopsy during the screening period. 7. Must be willing to provide blood samples and, if considered safe by the Investigator, a tumor biopsy specimen at 8 weeks after the start of treatment. 8. Ability to attend required study visits and return for adequate follow-up, as required by this protocol. 9. Agreement to practice effective contraception for female subjects of child-bearing potential and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to 1 year after completion of therapy, and non-sterile male subjects must agree to use a condom for up to 4 months after treatment. Exclusion Criteria: 1. History of persistent grade 2 or higher (CTCAE Version 4.03) hematologic toxicity resulting from previous therapy. 2. Within 5 years prior to first dose of study treatment, any evidence of other active malignancies or brain metastasis except for controlled basal cell carcinoma; prior history of in situ cancer (eg, breast, melanoma, and cervical); prior history of prostate cancer that is not under active systemic treatment (except hormonal therapy) and with undetectable PSA (< 0.2 ng/mL); and bulky (= 1.5 cm) disease with metastasis in the central hilar area of the chest and involving the pulmonary vasculature. 3. Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment-related complications. 4. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, and autoimmune disease associated with lymphoma) 5. History of organ transplant requiring immunosuppression. 6. History of or active inflammatory bowel disease (eg, Crohn's disease and ulcerative colitis). 7. Requires whole blood transfusion to meet eligibility criteria. 8. Inadequate organ function, evidenced by the following laboratory results: 1. WBC count < 2,500 cells/mm3 2. Absolute neutrophil count < 1,500 cells/mm3. 3. Platelet count < 100,000 cells/mm3. 4. Hemoglobin < 9 g/dL. 5. Total bilirubin greater than the ULN (unless the subject has documented Gilbert's syndrome). 6. AST (SGOT) or ALT (SGPT) > 2.5 × ULN (> 5 × ULN in subjects with liver metastases). 7. ALP levels > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases). 8. Serum creatinine > 2.0 mg/dL or 177 µmol/L. 9. INR, aPTT, or PTT >1.5 × ULN (unless on therapeutic anti-coagulation). 9. Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication. 10. Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy. 11. Positive results of screening test for HIV, HBV, or HCV. 12. Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed. 13. Known hypersensitivity to any component of the study medication(s). 14. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications. 15. Concurrent or prior use of a strong CYP3A4 inhibitor (including ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit products) or strong CYP3A4 inducers (including phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study day 1. 16. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8 inducer (rifampin) within 14 days before study day 1. 17. Participation in an investigational drug study or history of receiving any investigational treatment within 14 days prior to screening for this study, except for testosterone-lowering therapy in men with prostate cancer. 18. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol. 19. Concurrent participation in any interventional clinical trial. 20. Pregnant and nursing women.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
avelumab
Fully human anti-programmed death-ligand 1 (PD-L1) immunoglobulin (Ig)G1 lambda monoclonal antibody
bevacizumab
Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
Drug:
capecitabine
5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
Biological:
cetuximab
Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
Drug:
Cyclophosphamide
2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
5-Fluorouracil (5-FU)
5-fluoro-2,4 (1H,3H)-pyrimidinedione
fulvestrant
7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
leucovorin
Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
nab paclitaxel
5ß,20-Epoxy-1,2a,4,7ß,10ß,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Biological:
nivolumab
Human anti-programmed cell death protein 1 (PD-1) IgG4 kappa monoclonal antibody
Drug:
Lovaza
Omega-3-acid ethyl esters
oxaliplatin
cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
Radiation:
Stereotactic Body Radiation Therapy
(SBRT)
Biological:
ALT-803
recombinant human super agonist interleukin-15 (IL-15) complex
ETBX-011
adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine
ETBX-021
Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
ETBX-051
Ad5 [E1-, E2b-]-Brachyury vaccine
ETBX-061
Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
GI-4000
RAS yeast vaccine
GI-6207
CEA yeast vaccine
GI-6301
Brachyury yeast vaccine
haNK
NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
ImmunityBio, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Phase 1b primary endpoint (safety) 1 year
Primary Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Phase 2 primary endpoint (ORR by RECIST) 1 year
Primary ORR by Immune-related response criteria (irRC ) Phase 2 primary endpoint (ORR by irRC) 1 year
Secondary ORR by RECIST Version 1.1 Phase 1b secondary endpoint (ORR by RECIST) 1 year
Secondary ORR by irRC Phase 1b secondary endpoint (ORR by irRC) 1 year
Secondary Progression-free survival (PFS) by RECIST Version 1.1 Phase 1b and 2 secondary endpoint (PFS by RECIST) 2 year
Secondary PFS by irRC Phase 1b and 2 secondary endpoint (PFS by irRC) 2 years
Secondary Overall survival (OS): time from the date of first treatment to the date of death (any cause) Phase 1b and 2 secondary endpoint (OS) 2 years
Secondary Duration of response (DR): time from the date of first response (partial response (PR) or complete response (CR)) to the date of disease progression or death (any cause) whichever occurs first Phase 1b and 2 secondary endpoint (DR) 2 years
Secondary Disease control rate (DCR): confirmed complete response, partial response, or stable disease lasting for at least 2 months Phase 1b and 2 secondary endpoint (DCR) 2 months
Secondary Quality of life (QoL) by patient-reported outcome using the Functional Assessment of Cancer Therapy-Colorectal Cancer (FACT-C) questionnaire Phase 1b and 2 secondary endpoint (QoL) 2 years
Secondary Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03 Phase 2 secondary endpoint (AEs) 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A